Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 356Lymphoid 2Sarcoma 1Genitourinary 1

Conditions

Prostatic Neoplasms 657Carcinoma, Renal Cell 384Carcinoma, Non-Small-Cell Lung 242Urinary Bladder Neoplasms 235Breast Neoplasms 221Melanoma 193Ovarian Neoplasms 191Neoplasms 178Colorectal Neoplasms 160Kidney Neoplasms 152Neoplasm Metastasis 131Carcinoma, Transitional Cell 126Pancreatic Neoplasms 124Lung Neoplasms 121Stomach Neoplasms 113Squamous Cell Carcinoma of Head and Neck 106Sarcoma 99Head and Neck Neoplasms 89Uterine Cervical Neoplasms 87Carcinoma, Hepatocellular 79Triple Negative Breast Neoplasms 75Esophageal Neoplasms 75Endometrial Neoplasms 74Colonic Neoplasms 64Wilms Tumor 56Small Cell Lung Carcinoma 54Carcinoma, Ovarian Epithelial 48Neuroblastoma 47Liver Neoplasms 46Testicular Neoplasms 45

Interventions

MLN 8237 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Advanced Solid Tumors × Genitourinary × Clear all
NCT01094288 2019-02-15

A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen

Takeda

Phase 1 Completed
41 enrolled 31 charts
GenitourinaryOther solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡